Close

Amgen to invest $200m in new Singapore manufacturing facility

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Fluid Path Integrity: Ensuring Purity in Biomanufacturing

In the high-stakes arena of biomanufacturing, where tiny contaminants...

GMP Fluid Handling: Regulatory Compliance Explained

Fluid Handling in GMP Manufacturing: The Essence of Regulatory...

Single-Use Technologies in Biopharma Transform Manufacturing

The biopharmaceutical sector is being revolutionized by the demand...

Advances in Aseptic fluid transfer solutions

Sterility and Cross-Contamination: The Cornerstones of Modern Biopharma Manufacturing Biopharmaceutical...

Amgen is planning to invest $200m to construct a manufacturing facility in the Tuas Biomedical Park area of Singapore.

Company intends to begin the construction of the new facility shortly to expand the monoclonal antibody manufacturing capacity.

Amgen operations executive vice president Madhu Balachandran said the planning for the new Singapore facility is a part of the strategic global expansion.

“Singapore is an ideal location to further our manufacturing efforts based on its rich talent pool and friendly business environment,” Balachandran added.

New facility, which is expected to employ fresh recruits along with experienced staff, will manufacture both clinical and commercial products.

Latest stories